LSE:GSK
LSE:GSKPharmaceuticals

How Should Investors View GSK’s Valuation After Its Strong 2025 Share Price Rally?

If you are wondering whether GSK is still a smart buy after its big run or if most of the upside is already priced in, this article will help you frame that decision through a valuation lens. Despite a minor 0.5% slip over the last week, GSK is still up 1.4% over 30 days, 33.1% year to date and 43.1% over the past year, which naturally raises the question of whether the current price fairly reflects its prospects. That strong share price performance has come as investors have refocused on...
LSE:HSBA
LSE:HSBABanks

Has HSBC Run Too Far After a 47% 2025 Rally?

If you have been wondering whether HSBC Holdings is still good value after its huge run, you are not alone. This piece will walk through whether the current price still stacks up. The stock has climbed 3.4% over the last week, 8.9% over the past month, and a striking 46.8% year to date, building on 58.6% over 1 year and more than tripling over 5 years. Recently, investors have been reacting to a mix of macro headlines, from shifting interest rate expectations that affect global banks, to...